Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

leflunomide

Known as: alpha,alpha,alpha-Trifluoro-5-methyl-4-isoxazolecarboxy-P-toluidide, Lefunomide, N-(4-trifluoromethyphenyl)-5-methylisoxazole-4-carboxamide 
A derivative of isoxazole used for its immunosuppressive and anti-inflammatory properties. As a prodrug, leflunomide is converted to an active… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Recent insights in rheumatoid arthritis (RA) necessitated updating the European League Against Rheumatism (EULAR) RA management… Expand
  • table 1
  • table 3
  • table 2
  • figure 1
Is this relevant?
Review
2016
Review
2016
A European League Against Rheumatism (EULAR) task force was established to define points to consider on use of antirheumatic… Expand
  • table 1
  • table 2
  • table 2
  • table 3
  • table 3
Is this relevant?
Highly Cited
2006
Highly Cited
2006
BACKGROUND Polyoma BK virus produces an aggressively destructive nephropathy in approximately 3% to 8% of renal allografts, is… Expand
Is this relevant?
Highly Cited
2005
Highly Cited
2005
BACKGROUND We compared the safety and efficacy of leflunomide with that of methotrexate in the treatment of polyarticular… Expand
Is this relevant?
Highly Cited
2004
Highly Cited
2004
OBJECTIVE Current treatment options for psoriatic arthritis (PsA) are limited. Leflunomide, an oral pyrimidine synthesis… Expand
Is this relevant?
Highly Cited
2000
Highly Cited
2000
OBJECTIVE To compare the clinical efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis… Expand
Is this relevant?
Highly Cited
2000
Highly Cited
2000
Leflunomide is a selective inhibitor of de novo pyrimidine synthesis. In phase II and III clinical trials of active rheumatoid… Expand
Is this relevant?
Highly Cited
1999
Highly Cited
1999
CONTEXT Leflunomide is a reversible inhibitor of de novo pyrimidine synthesis shown to be effective in a phase 2 trial in 402… Expand
  • table 1
  • figure 1
  • table 3
  • table 2
  • table 4
Is this relevant?
Highly Cited
1999
Highly Cited
1999
Summary Background Phase II trials of leflunomide, an inhibitor of de-novo pyrimidine synthesis, have shown efficacy in… Expand
Is this relevant?
Highly Cited
1999
Highly Cited
1999
Leflunomide is a novel immunosuppressive and antiinflammatory agent currently being tested for treatment of autoimmune diseases… Expand
Is this relevant?